TNSN04045A1 - Compositions de valdecoxib a delitement intra-oral - Google Patents

Compositions de valdecoxib a delitement intra-oral

Info

Publication number
TNSN04045A1
TNSN04045A1 TNP2004000045A TNSN04045A TNSN04045A1 TN SN04045 A1 TNSN04045 A1 TN SN04045A1 TN P2004000045 A TNP2004000045 A TN P2004000045A TN SN04045 A TNSN04045 A TN SN04045A TN SN04045 A1 TNSN04045 A1 TN SN04045A1
Authority
TN
Tunisia
Prior art keywords
compositions
intraoral delivery
valdecoxib
valdecoxib compositions
delivery
Prior art date
Application number
TNP2004000045A
Other languages
English (en)
French (fr)
Inventor
Trang T Le
Blake C Ludwig
Joseph P Reo
Uday J Shah
Ken Yamamoto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN04045A1 publication Critical patent/TNSN04045A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2004000045A 2001-09-26 2004-03-23 Compositions de valdecoxib a delitement intra-oral TNSN04045A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
PCT/US2002/030161 WO2003026623A1 (en) 2001-09-26 2002-09-23 Intraorally disintegrating valdecoxib compositions

Publications (1)

Publication Number Publication Date
TNSN04045A1 true TNSN04045A1 (fr) 2006-06-01

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2004000045A TNSN04045A1 (fr) 2001-09-26 2004-03-23 Compositions de valdecoxib a delitement intra-oral
TNP2004000047A TNSN04047A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TNP2004000047A TNSN04047A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Country Status (25)

Country Link
US (1) US20030181501A1 (https=)
EP (2) EP1490035A1 (https=)
JP (2) JP2005506987A (https=)
KR (2) KR20040044990A (https=)
CN (2) CN1633281A (https=)
AP (2) AP2004002999A0 (https=)
AR (1) AR037239A1 (https=)
BR (2) BR0212861A (https=)
CA (2) CA2461044A1 (https=)
CO (2) CO5570684A2 (https=)
EA (2) EA200400352A1 (https=)
EC (1) ECSP045029A (https=)
GE (1) GEP20063856B (https=)
HK (1) HK1079988A1 (https=)
IL (2) IL160855A0 (https=)
IS (2) IS7178A (https=)
MA (2) MA27682A1 (https=)
MX (2) MXPA04002798A (https=)
NO (2) NO20041258L (https=)
OA (2) OA12707A (https=)
PL (2) PL369298A1 (https=)
TN (2) TNSN04045A1 (https=)
WO (2) WO2003026623A1 (https=)
YU (1) YU34804A (https=)
ZA (2) ZA200401953B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
WO2006016602A1 (ja) * 2004-08-10 2006-02-16 Ajinomoto Co., Inc. 苦味の低減したナテグリニド含有製剤
US20080063710A1 (en) * 2004-12-28 2008-03-13 Eisai R&D Management Co., Ltd. Rapidly Disintegrating Tablet and Production Method Thereof
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1964549A1 (en) * 2005-12-20 2008-09-03 Eisai R&D Management Co., Ltd. Orally disintegrating tablet comprising fat-soluble substance
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
JP2009537554A (ja) * 2006-05-19 2009-10-29 ソマクソン ファーマシューティカルズ インコーポレイテッド 不眠症を治療するための、口腔内、舌下および急速融解製剤を含む、低用量ドキセピン製剤、ならびにその使用
US8685457B2 (en) * 2007-06-06 2014-04-01 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
CN102083410B (zh) * 2007-06-06 2013-04-17 巴斯夫欧洲公司 用于制备迅速崩解的片剂的药物制剂
JP2010529073A (ja) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
KR20160083132A (ko) * 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
CN101820838B (zh) * 2007-08-07 2013-06-05 阿塞尔Rx制药有限公司 采用口腔经粘膜剂型的用于程序镇静和镇痛的组合物和方法
EP2268268A2 (en) * 2008-03-24 2011-01-05 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
CN102223880B (zh) * 2008-11-25 2017-04-26 田边三菱制药株式会社 口腔速崩片及其制备方法
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
SK74396A3 (en) * 1995-06-13 1997-04-09 American Home Prod Organoleptically acceptable oral pharmaceutical compositions
JPH11513641A (ja) * 1995-10-20 1999-11-24 ファルマシア・アンド・アップジョン・カンパニー ブリスターパッケージ
CN1140267C (zh) * 1996-05-17 2004-03-03 麦克公司 治疗环加氧酶-2介导的疾病的每天一次的组合物
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
JP2003516353A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション ヴァルデコキシブ組成物
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP2004506680A (ja) * 2000-08-18 2004-03-04 ファルマシア・コーポレーション シクロオキシゲナーゼ−2阻害剤の迅速崩壊経口製剤

Also Published As

Publication number Publication date
US20030181501A1 (en) 2003-09-25
IS7178A (is) 2004-03-11
EA200400352A1 (ru) 2004-12-30
KR20040044990A (ko) 2004-05-31
IL160848A0 (en) 2004-08-31
KR20040058189A (ko) 2004-07-03
WO2003026623A8 (en) 2004-09-30
CO5570684A2 (es) 2005-10-31
OA13060A (en) 2006-11-10
BR0212778A (pt) 2004-12-07
CA2461630A1 (en) 2003-04-03
EP1490035A1 (en) 2004-12-29
GEP20063856B (en) 2006-06-26
MXPA04002652A (es) 2004-06-07
AR037239A1 (es) 2004-11-03
CN1703203A (zh) 2005-11-30
JP2005512964A (ja) 2005-05-12
ECSP045029A (es) 2004-04-28
MA27682A1 (fr) 2006-01-02
IS7177A (is) 2004-03-11
ZA200402364B (en) 2005-01-13
IL160855A0 (en) 2004-08-31
CO5570659A2 (es) 2005-10-31
AP2004002999A0 (en) 2004-03-31
WO2003026697A3 (en) 2003-07-03
NO20041532L (no) 2004-04-15
EA200400357A1 (ru) 2004-08-26
MXPA04002798A (es) 2004-07-05
JP2005506987A (ja) 2005-03-10
OA12707A (en) 2006-06-26
HK1079988A1 (zh) 2006-04-21
NO20041258L (no) 2003-03-27
AP2004002998A0 (en) 2004-03-31
PL369298A1 (en) 2005-04-18
PL369297A1 (en) 2005-04-18
MA27542A1 (fr) 2005-10-03
CA2461044A1 (en) 2003-04-03
WO2003026697A2 (en) 2003-04-03
TNSN04047A1 (fr) 2006-06-01
CN1633281A (zh) 2005-06-29
BR0212861A (pt) 2004-10-05
YU34804A (sh) 2006-08-17
EP1429736A2 (en) 2004-06-23
WO2003026623A1 (en) 2003-04-03
ZA200401953B (en) 2005-05-09

Similar Documents

Publication Publication Date Title
TNSN04045A1 (fr) Compositions de valdecoxib a delitement intra-oral
Chumbley et al. The effect of indomethacin (an aspirin-like drug) on the rate of orthodontic tooth movement
Samra et al. Tooth supported overdenture: A concept overshadowed but not yet forgotten!
TR200002207T1 (tr) Slekoksib bileşikleri.
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
DK0831791T3 (da) Transport af lægemiddelstoffer til den nedre gastrointestinalkanal
Eshghpour et al. Effectiveness of green tea mouthwash in postoperative pain control following surgical removal of impacted third molars: double blind randomized clinical trial
BR0215133A (pt) Placa mio-relaxante intra-oral e método para sua utilização
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
MY144781A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
TNSN96101A1 (fr) Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
TNSN04056A1 (fr) Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation
TNSN00163A1 (fr) Composition pour la prevention et le traitement des dysfonctions et des maladies renales
FR2774289B1 (fr) Medicament pour le traitement des dereglements de l'apoptose
Axéll Treatment of smarting symptoms in the oral mucosa by appliance of lingual acrylic splints
Landes Photocure acrylic individual splints in orthognathic surgery
UCHIDA et al. Clinical evaluation of CS-670 in the treatment of postexodontic pain A multicenter double-blind study
Gurumoorthy et al. Multiple acute periodontal abscesses due to clenching
Wolfinger et al. Prosthodontic management of a combination transosteal/endosteal implant reconstruction: a clinical report
DAWSON et al. Treatment of a traumatic ulcer on a handicapped individual: a case report